Dabigatran versus warfarin in patients with atrial fibrillation

Cited by (1,022)

Items 201–300 of 1,022

1. Parenteral anticoagulants in heart disease: Current status and perspectives (Section II)
   Steen Husted, Lars C. Wallentin, Felicita Andreotti, Harald Arnesen, F Bachmann, Colin Baigent, Kurt Huber, Jørgen Jespersen, Steen Dalby Kristensen, Gregory Y.H. Lip et al. · 2013 · Thrombosis and Haemostasis
2. Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries
   Jonas Oldgren, Jeff S. Healey, Michael D. Ezekowitz, Patrick Commerford, Álvaro Avezum, Prem S Pais, Jun Zhu, Petr Janský, Alben Sigamani, Carlos Arturo Morillo et al. · 2014 · Circulation
3. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
   Michael Glikson, Rafael Wolff, Gerhard Hindricks, John M. Mandrola, A. John Camm, Gregory Y.H. Lip, Laurent Fauchier, Timothy R. Betts, Thorsten Lewalter, Jacqueline Saw et al. · 2020 · EuroIntervention
4. Atrial fibrillation in heart failure: what should we do?
   Dipak Kotecha, Jonathan Paul Piccini · 2015 · European Heart Journal
5. Vitamin K antagonists in heart disease: Current status and perspectives (Section III)
   Steen Husted, Lars C. Wallentin, Felicita Andreotti, Harald Arnesen, Fedor Bachmann, Colin Baigent, Kurt Huber, Jørgen Jespersen, Steen Dalby Kristensen, Gregory Y.H. Lip et al. · 2013 · Thrombosis and Haemostasis
6. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications
   Samer Narouze, Honorio T. Benzon, David Anthony Provenzano, Asokumar Buvanendran, José Antonio De Andrés, Timothy Ray Deer, Richard L Rauck, Marc Alan Huntoon · 2015 · Regional Anesthesia & Pain Medicine
7. Radiofrequency Catheter Ablation of Atrial Fibrillation: A Cause of Silent Thromboembolism?
   Fiorenzo Gaïta, Domenico Caponi, Martina Pianelli, Marco Scaglione, Elisabetta Toso, Federico Cesarani, Carlo Boffano, G Gandini, Maria Consuelo Valentini, Roberto De Ponti et al. · 2010 · Circulation
8. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients
   Arlene M. Gallagher, Efrosini Setakis, Jonathan Plumb, Andreas Clemens, Tjeerd Pieter van Staa · 2011 · Thrombosis and Haemostasis
9. Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation
   Dhanunjaya Lakkireddy, Yeruva Madhu Reddy, Luigi Di Biase, Subba Reddy Vanga, Pasquale Santangeli, Vijay Swarup, Rhea Pimentel, MOUSSA C. MANSOUR, André d’Ávila, Javier Sánchez et al. · 2012 · Journal of the American College of Cardiology
10. Dabigatran and Postmarketing Reports of Bleeding
    Mary Ross Southworth, Marsha E. Reichman, Ellis F. Unger · 2013 · New England Journal of Medicine
11. Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial
    Stefan Hans Hohnloser, Jonas Oldgren, Sean Yang, Lars C. Wallentin, Michael D. Ezekowitz, Paul A. Reilly, John W. Eikelboom, Martina Brueckmann, Salim Yusuf, Stuart J. Connolly · 2012 · Circulation
12. Dabigatran Etexilate
    Graeme J. Hankey, John W. Eikelboom · 2011 · Circulation
13. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
    Neena S. Abraham, Sonal Singh, G. Caleb Alexander, Herbert C. Heien, Lindsey R. Haas, William H. Crown, Nilay D. Shah · 2015 · BMJ
14. Guidance for the treatment of deep vein thrombosis and pulmonary embolism
    Michael Blake Streiff, Giancarlo Agnelli, Jean M. Connors, Mark Andrew Crowther, Sabine Eichinger, Renato D. Lópes, Robert D. McBane, Stephan Moll, Jack Ansell · 2016 · Journal of Thrombosis and Thrombolysis
15. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants
    Bethany Samuelson Bannow, Adam C. Cuker, Deborah M. Siegal, Mark Andrew Crowther, David A. Garcia · 2016 · CHEST Journal
16. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
    Peter Brønnum Nielsen, Flemming Skjøth, Mette Søgaard, Jette Nordstrøm Kjældgaard, Gregory Y.H. Lip, Torben Bjerregaard Larsen · 2017 · BMJ
17. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation
    Ken Okumura, Masaharu Akao, Tetsuro Yoshida, Masahito Kawata, Osamu Okazaki, Shintaro Akashi, Kenichi Eshima, Kimihiko Tanizawa, Masayuki Fukuzawa, Takuya Hayashi et al. · 2020 · New England Journal of Medicine
18. Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
    Hylek, Elaine M., Held, Claes, Alexander, John H., Lopes, Renato D., De Caterina, Raffaele, Wojdyla, Daniel M., Huber, Kurt, Jansky, Petr, Steg, Philippe Gabriel, Hanna, Michael et al. · 2014 · Journal of the American College of Cardiology
19. Cardiohepatic Interactions in Heart Failure
    Marc D. Samsky, Chetan B. Patel, Tracy A. DeWald, Alastair D. Smith, Gary Michael Felker, Joseph G. Rogers, Adrian F. Hernandez · 2013 · Journal of the American College of Cardiology
20. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
    Perry M Elliot, Aris Anastasakis, Michael Andrew Borger, Martin Borggrefe, Franco Cecchi, Philippe Charron, Albert Alain Hagège, Antoine M. Lafont, Giuseppe Limongelli, Heiko Mahrholdt et al. · 2014 · Kardiologia Polska
21. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
    Stuart J. Connolly, Indravadan J. Patel, Daniel E. Salazar, Shashank Rohatagi, Jeanne Mendell, Helen Kastrissios, Jianqing Jin, Satoshi Kunitada, Jeffrey Ian Weitz · 2010 · Thrombosis and Haemostasis
22. 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures
    György Frendl, Alissa Sodickson, Mina K. Chung, Albert L. Waldo, Bernard John Gersh, James Edward Tisdale, Hugh G Calkins, Sary F. Aranki, Tsuyoshi Kaneko, Stephen D. Cassivi et al. · 2014 · Journal of Thoracic and Cardiovascular Surgery
23. Atrial fibrillation
    Gregory Y.H. Lip, Hung‐Fat Tse, Deirdre A. Lane · 2011 · The Lancet
24. Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
    Shimoli V. Shah, Brian F. Gage · 2011 · Circulation
25. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
    Allison Burnett, Charles Edward Mahan, Sara R. Vazquez, Lynn B. Oertel, David A. Garcia, Jack Ansell · 2016 · Journal of Thrombosis and Thrombolysis
26. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
    Michael Glikson, Rafael Wolff, Gerhard Hindricks, John M. Mandrola, Alan John Camm, Gregory Y.H. Lip, Laurent Fauchier, Timothy R. Betts, Thorsten Lewalter, Jacqueline Saw et al. · 2019 · EP Europace
27. Intracranial Hemorrhage
    J. Caceres, Joshua Norkin Goldstein · 2012 · Emergency Medicine Clinics of North America
28. Dabigatran Versus Warfarin
    Masatsugu Hori, Stuart J. Connolly, Jun Zhu, Lisheng Liu, Chu‐Pak Lau, Prem S Pais, Denis Xavier, Sung Soon Kim, Razali Omar, Antonio L. Dans et al. · 2013 · Stroke
29. Screening to identify unknown atrial fibrillation: A systematic review
    Lowres, Nicole, Neubeck, Lis, Redfern, Julie, Freedman, S. Ben · 2013 · Thrombosis and Haemostasis
30. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018
    David B. Brieger, John V. Amerena, John Attia, Beata V. Bajorek, Kim Hoe Chan, Cia Connell, Ben Freedman, Caleb Ferguson, Tanya L Hall, Haris M. Haqqani et al. · 2018 · Heart Lung and Circulation
31. Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice: Insight From the Real-Life Global Survey Evaluating Patients With Atrial Fibrillation International Registry
    Chiang, Chern-En, Naditch-Brûlé, Lisa, Murin, Jan, Goethals, Marnix, Inoue, Hiroshi, O’Neill, James, Silva-Cardoso, Jose, Zharinov, Oleg, Gamra, Habib, Alam, Samir et al. · 2012 · Circulation: Arrhythmia and Electrophysiology
32. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis
    Chatree Chai‐Adisaksopha, Mark Andrew Crowther, Tetsuya Isayama, Wendy Lim · 2014 · Blood
33. Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
    Kevin E. Chan, Elazer Reuven Edelman, Julia Wenger, Ravi Thadhani, Franklin W. Maddux · 2015 · Circulation
34. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion
    Bernhard Meier, Yuri Blaauw, Ahmed Aziz Khattab, Torsten Lewalter, Horst Sievert, Claudio Tondo, Michael Glikson, ESC Scientific Document Group, Gregory Y.H. Lip, José Ramón López-Mínguez et al. · 2014 · EP Europace
35. Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran
    Wei Zhou, Sönke Schwarting, Sergio Illanes, Arthur Liesz, Moritz A. Middelhoff, Markus Zorn, Martin Bendszus, Sabine Heiland, Joanne van Ryn, Roland C. Veltkamp · 2011 · Stroke
36. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients
    Gregory Y.H. Lip, Allison V. Keshishian, Xiaoyan Li, Melissa Hamilton, Cristina Masseria, Kiran B. Gupta, Xuemei Luo, Jack Mardekian, Keith E. Friend, Anagha Nadkarni et al. · 2018 · Stroke
37. Impact of dabigatran on a large panel of routine or specific coagulation assays
    Séverine Robert, Christian Chatelain, Jonathan Douxfils, François Mullier, Bernard Châtelain, Jean‐Michel Dogné · 2012 · Thrombosis and Haemostasis
38. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials
    Giuseppe Gargiulo, Andreas Goette, Jan G.P. Tijssen, Lars Eckardt, Thorsten Lewalter, Pascal Vranckx, Marco Valgimigli · 2019 · European Heart Journal
39. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy
    Bernard John Gersh, Barry J. Maron, Robert O. Bonow, Joseph A. Dearani, Michael A. Fifer, Mark S. Link, Srihari S. Naidu, Rick A. Nishimura, Steve R. Ommen, Harry Rakowski et al. · 2011 · Journal of Thoracic and Cardiovascular Surgery
40. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial
    Stephan Glund, Joachim Stangier, Michael Schmohl, Dietmar Ganßer, Stephen H. Norris, Joanne van Ryn, Benjamin J. Lang, Steven Ramael, Viktoria Moschetti, Fredrik I. Gruenenfelder et al. · 2015 · The Lancet
41. Gender differences in the effects of cardiovascular drugs
    Juan Luis Tamargo, Giuseppe M.C. Rosano, Thomas Walther, Juan Duarte, Alexander Niessner, JC Kaski, Claudio Ceconi, Heinz Drexel, Keld P. Kjeldsen, Gianluigi Savarese et al. · 2016 · European Heart Journal - Cardiovascular Pharmacotherapy
42. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES
    Vanassche, T., Lauw, M. N., Eikelboom, J. W., Healey, J. S., Hart, R. G., Alings, M., Avezum, A., Diaz, R., Hohnloser, S. H., Lewis, B. S. et al. · 2015 · European Heart Journal
43. Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study
    Marijon, Eloi, Le Heuzey, Jean-Yves, Connolly, Stuart, Yang, Sean, Pogue, Janice, Brueckmann, Martina, Eikelboom, John, Themeles, Ellison, Ezekowitz, Michael, Wallentin, Lars et al. · 2013 · Circulation
44. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation
    David J. Graham, Marsha E. Reichman, Michael Wernecke, Ya-Hui Hsueh, Rima Izem, Mary Ross Southworth, Yuqin Wei, Jiemin Liao, Margie R. Goulding, Katrina Mott et al. · 2016 · JAMA Internal Medicine
45. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis
    José Manuel Ferro, Jonathan M. Coutinho, Francesco Dentali, Adam Kobayashi, Andrey Marisovich Alasheev, Patrícia Canhão, Denis Karpov, Simon Nagel, Laura Posthuma, José Mário Roriz et al. · 2019 · JAMA Neurology
46. Deep neural networks can predict new-onset atrial fibrillation from the 12-lead ECG and help identify those at risk of atrial fibrillation-related stroke
    Raghunath, Sushravya, Pfeifer, John M., Ulloa-Cerna, Alvaro E., Nemani, Arun, Carbonati, Tanner, Jing, Linyuan, vanMaanen, David P., Hartzel, Dustin N., Ruhl, Jeffery A., Lagerman, Braxton F. et al. · 2021 · Circulation
47. National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011
    Kate Kirley, Dima Mazen Qato, Rachel Kornfield, Randall Scott Stafford, G. Caleb Alexander · 2012 · Circulation Cardiovascular Quality and Outcomes
48. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013
    Gilles Pernod, Pierre Albaladejo, Anne Godiér, Charles Marc Samama, Sophie Susen, Yves Gruel, Normand Blais, Pierre Fontana, Ariel A. Cohen, Juan V. Llau et al. · 2013 · Archives of cardiovascular diseases
49. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial
    K. Liesenfeld, T. Lehr, C. Dansirikul, P. Reilly, S. Connolly, M. Ezekowitz, S. Yusuf, L. Wallentin, S. Haertter, A. Staab · 2011 · Journal of Thrombosis and Haemostasis
50. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex
    Anthony Carnicelli, Hwanhee Hong, Stuart J. Connolly, John W. Eikelboom, Robert Patrick Giugliano, David A. Morrow, Manesh R. Patel, Lars C. Wallentin, John Hunter Alexander, Maria Cecilia Bahit et al. · 2022 · Archive ouverte UNIGE (University of Geneva)
51. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation
    Stylianos E. Tzeis, Edward P. Gerstenfeld, Jonathan M. Kalman, Eduardo Saad, Alireza Sepehri Shamloo, Jason G. Andrade, Chirag R. Barbhaiya, Tina Baykaner, Serge Bovéda, Hugh G Calkins et al. · 2024 · Heart Rhythm
52. Cardiovascular Research Using the Korean National Health Information Database
    Eue‐Keun Choi · 2020 · Korean Circulation Journal
53. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study
    Amitava Banerjee, Deirdre A. Lane, Christian Tobias Torp-Pedersen, Gregory Y.H. Lip · 2011 · Thrombosis and Haemostasis
54. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines
    Andrew Veitch, Geoffroy Vanbiervliet, Anthony Gershlick, Christian Boustière, Trevor P Baglin, Lesley‐Ann Smith, Franco Radaelli, Evelyn Knight, Ian Mark Gralnek, Cesare Hassan et al. · 2016 · Gut
55. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
    Elisabeth Perzborn, Susanne Roehrig, Alexander Straub, Dagmar Kubitza, Frank Misselwitz · 2010 · Nature Reviews Drug Discovery
56. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society
    Cecilia Marianne Linde, Maria Grazia Bongiorni, Ulrika Maria Birgersdotter-Green, Anne B. Curtis, Isabel Deisenhofer, Tetsushi Furokawa, Anne M. Gillis, Kristina Hermann Haugaa, Gregory Y.H. Lip, Isabelle C. Van Gelder et al. · 2018 · EP Europace
57. Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality
    Vermond, Rob A., Geelhoed, Bastiaan, Verweij, Niek, Tieleman, Robert G., Van der Harst, Pim, Hillege, Hans L., Van Gilst, Wiek H., Van Gelder, Isabelle C., Rienstra, Michiel · 2015 · Journal of the American College of Cardiology
58. Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk
    Jonathan Chong Hsu, Thomas M. Maddox, Kevin F. Kennedy, David F. Katz, Lucas Marzec, Steven A. Lubitz, Anil K. Gehi, Mintu P. Turakhia, Gregory M. Marcus · 2016 · JAMA Cardiology
59. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial
    Renato D. Lópes, Marco Alings, Stuart J. Connolly, Heather Beresh, Christopher Bull Granger, Juan Benezet Mazuecos, Giuseppe Boriani, Jens Cosedis Nielsen, David Conen, Stefan Hans Hohnloser et al. · 2017 · American Heart Journal
60. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
    Mintu P. Turakhia, Peter J. Blankestijn, Juan Jesús Carrero, Catherine M. Clase, Rajat Deo, Charles A. Herzog, Scott Eric Kasner, ROD S. PASSMAN, Roberto Pecoits‐Filho, Holger Reinecke et al. · 2018 · European Heart Journal
61. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve
    Hélio Penna Guimarães, Renato D. Lópes, Pedro Gabriel Melo de Barros e Silva, Idelzuita Leandro Liporace, Roney Orismar Sampaio, Flávio Tarasoutchi, Conrado Roberto Hoffmann Filho, Rodrigo de Lemos Soares Patriota, Tiago Luiz Luz Leiria, Diana Lamprea et al. · 2020 · New England Journal of Medicine
62. Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter
    John A. Cairns, Stuart J. Connolly, Sean McMurtry, Michael Stephenson, Mario R. Talajic · 2011 · Canadian Journal of Cardiology
63. The new oral anticoagulants
    David A. Garcia, Edward N. Libby, Mark Andrew Crowther · 2009 · Blood
64. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation
    Gregory Y.H. Lip, Torben Bjerregaard Larsen, Flemming Skjøth, Lars Hvilsted Rasmussen · 2012 · Journal of the American College of Cardiology
65. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
    Clyde W. Yancy, Mariell L Jessup, Biykem Bozkurt, Javed Butler, Donald E. Casey, Mark H. Drazner, Gregg C. Fonarow, Stephen A. Geraci, Tamara B. Horwich, James L. Januzzi et al. · 2013 · Journal of the American College of Cardiology
66. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments
    Jessica L. Mega, Tabassome Simon · 2015 · The Lancet
67. Stroke prevention in atrial fibrillation: An Asian perspective
    Kang-Ling Wang, Gregory Y.H. Lip, Chern‐En Chiang · 2014 · Thrombosis and Haemostasis
68. Bleeding Risk with Dabigatran in the Frail Elderly
    Paul L. Harper, Laura D. Young, Eileen Merriman · 2012 · New England Journal of Medicine
69. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study
    Jeff S. Healey, Jonas Oldgren, Michael D. Ezekowitz, Jun Zhu, Prem Pais, Jia Wang, Patrick Commerford, Petr Janský, Álvaro Avezum, Alben Sigamani et al. · 2016 · The Lancet
70. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care
    Y. Vinogradova, C. Coupland, T. Hill, J. Hippisley-Cox · 2018 · British medical journal
71. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial
    J. Donald Easton, Renato D. Lópes, Maria Cecilia Bahit, DANIEL M. WOJDYLA, Christopher Bull Granger, Lars C. Wallentin, Marco Alings, Shinya Goto, Basil S. Lewis, Mårten Rosenqvist et al. · 2012 · The Lancet Neurology
72. Bleeding risk assessment and management in atrial fibrillation patients
    Laurent Fauchier, Elaine M. Hylek, Eve Knight, Deirdre A. Lane, Marcel M Levi, Francisco R. Marín, Gualtiero Palareti, Collet Jp, Andrea Rubboli, Daniela Poli et al. · 2011 · Thrombosis and Haemostasis
73. The Changing Landscape for Stroke Prevention in AF
    Menno Volkert Huisman, Kenneth Jay Rothman, Miney Paquette, Christine Teutsch, Hans‐Christoph Diener, Sérgio Dubner, Jonathan L. Halperin, Chang Sheng, Kristina Zint, Amelie Elsaesser et al. · 2017 · Journal of the American College of Cardiology
74. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary
    Bernard John Gersh, Barry J. Maron, Robert O. Bonow, Joseph A. Dearani, Michael A. Fifer, Mark S. Link, Srihari S. Naidu, Rick A. Nishimura, Steve R. Ommen, Harry Rakowski et al. · 2011 · Journal of the American College of Cardiology
75. Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
    Ammar Majeed, Hun-Gyu Hwang, Stuart J. Connolly, John W. Eikelboom, Michael D. Ezekowitz, Lars C. Wallentin, Martina Brueckmann, Mandy Fraessdorf, Salim Yusuf, Sam Schulman · 2013 · Circulation
76. Moving the Tipping Point
    Mark H. Eckman, Daniel E. Singer, Jonathan M. Rosand, Steven Mark Greenberg · 2010 · Circulation Cardiovascular Quality and Outcomes
77. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR
    Nicolas M. Van Mieghem, Martin Unverdorben, Christian Hengstenberg, Helge Möllmann, Roxana Mehran, Diego López-Otero, Luis Nombela-Franco y, Raul Moreno, Peter Nordbeck, Holger Thiele et al. · 2021 · New England Journal of Medicine
78. A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice
    Tjeerd Pieter van Staa, Efrosini Setakis, Gian Luca Di Tanna, Deirdre A. Lane, Gregory Y.H. Lip · 2010 · Journal of Thrombosis and Haemostasis
79. Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes
    Stacy B. Westerman, NANETTE KASS WENGER · 2018 · Current Cardiology Reviews
80. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation
    Laurent Macle, John A. Cairns, Kori Leblanc, Teresa S.M. Tsang, Allan Cameron Skanes, Jafna L. Cox, Jeff S. Healey, Alan Bell, Louise Pilote, Jason G. Andrade et al. · 2016 · Canadian Journal of Cardiology
81. 2020 ACC/AHA guideline for the management of patients with valvular heart disease
    Otto, Catherine M., Nishimura, Rick A., Bonow, Robert O., Carabello, Blase A., Erwin, John P., Gentile, Federico, Jneid, Hani, Krieger, Eric V., Mack, Michael, McLeod, Christopher et al. · 2021 · The Journal of Thoracic and Cardiovascular Surgery
82. Left Ventricular Thrombus After Acute Myocardial Infarction
    Cian P. McCarthy, Muthiah Vaduganathan, Killian J. McCarthy, James L. Januzzi, Deepak L. Bhatt, John William McEvoy · 2018 · JAMA Cardiology
83. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
    Karen L. Furie, Larry B. Goldstein, Gregory W. Albers, Pooja Khatri, Ron R. Neyens, Mintu P. Turakhia, Tanya N. Turan, Kathryn Wood · 2012 · Stroke
84. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
    Fariba Baghaei, Inger Fagerberg, Kerstin M. Gustafsson, Lennart Stigendal, Margareta Sten-Linder, Karin Strandberg, Andreas Hillarp, Tomas L. Lindahl, and from the expert group on coagulation of the External Quality Assurance in Laboratory Medicine in Sweden · 2010 · Thrombosis and Haemostasis
85. Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation
    Matthew William Sherwood, James Demetrios Douketis, Manesh R. Patel, Jonathan Paul Piccini, Anne S. Hellkamp, Yuliya V. Lokhnygina, Alex C. Spyropoulos, Graeme J. Hankey, Daniel E. Singer, Christopher C. Nessel et al. · 2014 · Circulation
86. New Oral Anticoagulants in Elderly Adults: Evidence from a Meta‐Analysis of Randomized Trials
    Partha Sardar, Saurav Chatterjee, Shobhana Chaudhari, Gregory Y.H. Lip · 2014 · Journal of the American Geriatrics Society
87. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin
    Allison V. Keshishian, Shital Kamble, Xianying Pan, Jack Mardekian, Ruslan V. Horblyuk, Melissa Hamilton, Gregory Y.H. Lip · 2016 · Thrombosis and Haemostasis
88. New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes
    Raffaele De Caterina, Steen Husted, Lars C. Wallentin, Raffaele De Caterina, Steen Husted, Lars C. Wallentin, Felicita Andreotti, Harald Arnesen, F Bachmann, Colin Baigent et al. · 2012 · Journal of the American College of Cardiology
89. Causes of Death in Anticoagulated Patients With Atrial Fibrillation
    Antonio Gómez‐Outes, Julián Lagunar-Ruíz, Ana‐Isabel Terleira‐Fernández, Gonzalo Calvo, Maria Luisa Suárez-Gea, Emilio Vargas · 2016 · Journal of the American College of Cardiology
90. Risk of Bleeding With Dabigatran in Atrial Fibrillation
    Inmaculada Hernandez, Seo Hyon Baik, Antonio Piñera, Yuting Zhang · 2014 · JAMA Internal Medicine
91. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA
    Mattias Wieloch, Anders Själander, Viveka Frykman, Mårten Rosenqvist, Niclas Eriksson, Peter J. Svensson · 2011 · European Heart Journal
92. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013):– Digest Version –
    JCSJointWorkingGroup · 2014 · Circulation
93. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation
    Aya Fukuma Ozaki, A. Choi, Quan T. Le, Dennis T. Ko, Janet K. Han, Sandy S. Park, Cynthia Anne Jackevicius · 2020 · Circulation Cardiovascular Quality and Outcomes
94. Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
    Amanda R. Harrington, Edward P. Armstrong, Paul E. Nolan, Daniel C. Malone · 2013 · Stroke
95. Anticoagulation Drug Therapy: A Review
    Katherine Harter, Michael S. Levine, Sean O. Henderson · 2015 · Western Journal of Emergency Medicine
96. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?
    Chao, Tze-Fan, Liu, Chia-Jen, Wang, Kang-Ling, Lin, Yenn-Jiang, Chang, Shih-Lin, Lo, Li-Wei, Hu, Yu-Feng, Tuan, Ta-Chuan, Chen, Tzeng-Ji, Lip, Gregory Y.H. et al. · 2015 · Journal of the American College of Cardiology
97. Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding
    Guillaume Paré, Niclas Eriksson, Thorsten Lehr, Stuart J. Connolly, John W. Eikelboom, Michael D. Ezekowitz, Tomas Axelsson, Sebastian Haertter, Jonas Oldgren, Paul A. Reilly et al. · 2013 · Circulation
98. Hypertension and Atrial Fibrillation
    Paolo Verdecchia, Fabio Angeli, Gianpaolo Reboldi · 2018 · Circulation Research
99. Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association
    Amish N. Raval, Joaquin E. Cigarroa, Mina K. Chung, Larry J. Díaz‐Sandoval, Deborah Diercks, Jonathan Paul Piccini, Hee Soo Jung, Jeffrey B. Washam, Babu Guai Welch, Allyson R. Zazulia et al. · 2017 · Circulation
100. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation
     Xiaoxi Yao, Navdeep Tangri, Bernard John Gersh, Lindsey R. Sangaralingham, Nilay D. Shah, Karl A. Nath, Peter A. Noseworthy · 2017 · Journal of the American College of Cardiology